A detailed history of R Squared LTD transactions in Macrogenics Inc stock. As of the latest transaction made, R Squared LTD holds 570 shares of MGNX stock, worth $1,749. This represents 0.0% of its overall portfolio holdings.

Number of Shares
570
Holding current value
$1,749
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$3.18 - $4.46 $1,812 - $2,542
570 New
570 $1.85 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $189M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track R Squared LTD Portfolio

Follow R Squared LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of R Squared LTD, based on Form 13F filings with the SEC.

News

Stay updated on R Squared LTD with notifications on news.